Targeting angiogenesis, for instance, with VEGF inhibitors can disrupt the tumor blood supply and normalize abnormal tumor vasculature, improving the delivery of chemotherapeutic agents and immune cells to the tumor [112]. Here, VEGFA is linked to neoplasm.